Fig. 5From: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMonthly mean change in moderate-to-severemigraine headache days. **p≤0.01 vsPBO; ***p≤0.001 vs PBO. GMB,galcanezumab; LS, least squares; PBO, placebo; SE, standard errorBack to article page